{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T06:40:26Z","timestamp":1767595226600,"version":"3.48.0"},"reference-count":30,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The updated JN.1 monovalent vaccine (MoV) for the 2024\u20132025 season elicits strong cross-neutralizing activity against subsequently circulating SARS-CoV-2 variants in 2025, including the recently emerging NB.1.8.1, with titer increases comparable to those against the vaccine strain JN.1. The immune response induced by the JN.1 MoV was markedly stronger than that induced by XBB.1.5 MoV in the previous season, both against the vaccine strain and post-vaccine variant (all\n                    <jats:italic>P<\/jats:italic>\n                    &amp;lt; 0.001). These results likely reflect improved background immunity to circulating variants and support the use of catch-up booster vaccination during the summer surge, particularly for high-risk groups.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1696676","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T06:38:32Z","timestamp":1767595112000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Robust neutralization of emerging JN.1 subvariants by the updated JN.1 vaccine: rationale for catch-up booster recommendations in high-risk individuals"],"prefix":"10.3389","volume":"16","author":[{"given":"Ju-yeon","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su-Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soyoung","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye Min","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Jae","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye-Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dokeun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Hoon","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hye-Sook","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2215780","article-title":"Bivalent covid-19 vaccines - A cautionary tale","volume":"388","author":"Offit","year":"2023","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad363","article-title":"Immune response kinetics following a third heterologous BNT162b2 booster dose after primary 2-dose chAdOx1 vaccination in relation to omicron breakthrough infection: A prospective nationwide cohort study in South Korea","volume":"10","author":"Ahn","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e29285","DOI":"10.1002\/jmv.29285","article-title":"Evolution of neutralizing antibodies through vaccination and breakthrough infections in the era of COVID-19 endemicity","volume":"95","author":"Yang","year":"2023","journal-title":"J Med Virol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/20499361251314763","article-title":"The JN.1 variant of COVID-19: immune evasion, transmissibility, and implications for global health","volume":"12","author":"Naveed Siddiqui","year":"2025","journal-title":"Ther Adv Infect Dis"},{"key":"B5","unstructured":"Tracking of hCoV-19 Variants"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(25)00356-1","article-title":"Virological characteristics of the SARS-CoV-2 NB.1.8.1 variant","volume":"25","author":"Uriu","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/infdis\/jiae536","article-title":"Natural boosting and the immunogenicity of the XBB.1.5 monovalent vaccine in the coronavirus disease 2019 endemic era: A longitudinal observational study","volume":"231","author":"Kang","year":"2025","journal-title":"J Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiph.2025.102794","article-title":"Diminishing reactogenicity with preserved immunogenicity in COVID-19 vaccines: A longitudinal observation from primary to updated booster vaccine cohorts","volume":"18","author":"Kang","year":"2025","journal-title":"J Infect Public Health"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00527-4","article-title":"WHO International Standard for anti-SARS-CoV-2 immunoglobulin","volume":"397","author":"Kristiansen","year":"2021","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2021.104820","article-title":"Performance of the rapid high-throughput automated electrochemiluminescence immunoassay targeting total antibodies to the SARS-CoV-2 spike protein receptor binding domain in comparison to the neutralization assay","volume":"139","author":"Resman Rus","year":"2021","journal-title":"J Clin Virol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e0266922","DOI":"10.1128\/spectrum.02669-22","article-title":"Estimation of SARS-coV-2 neutralizing activity and protective immunity in different vaccine types using three surrogate virus neutralization test assays and two semiquantitative binding assays targeting the receptor-binding domain","volume":"10","author":"Lee","year":"2022","journal-title":"Microbiol Spectr"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.822599","article-title":"Estimating the neutralizing effect and titer correlation of semi-quantitative anti-SARS-coV-2 antibody immunoassays","volume":"12","author":"Lee","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2023.38.e292","article-title":"Clinical utility of sero-immunological responses against SARS-coV-2 nucleocapsid protein during subsequent prevalence of wild-type, delta variant, and omicron variant","volume":"38","author":"Lee","year":"2023","journal-title":"J Korean Med Sci"},{"key":"B14","unstructured":"Tracking SARS-CoV-2 variants\n          \n          \n          \n          2025"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.968105","article-title":"Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea","volume":"13","author":"Nham","year":"2022","journal-title":"Front Immunol"},{"key":"B16","unstructured":"Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic\n          \n          \n          \n          2023"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(25)00308-1","article-title":"Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1","volume":"25","author":"Guo","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B18","unstructured":"Statement on the antigen composition of COVID-19 vaccines\n          \n          \n          \n          2025"},{"key":"B19","unstructured":"COVID-19 Vaccines (2025\u20132026 Formula) for Use in the United States Beginning in Fall 2025\n          \n          \n          \n          2025"},{"key":"B20","unstructured":"ETF recommends updating COVID-19 vaccines to target new LP.8.1 variant\n          \n          \n          \n          2025"},{"key":"B21","unstructured":"Weekly COVID-19 Vaccination Dashboard\n          \n          \n          \n          2025"},{"key":"B22","unstructured":"European Centre for Disease Prevention and Control. Surveillance report on interim COVID-19 vaccination coverage in the EU\/EEA, August 2024 \u2013 January 2025\n          \n          \n          \n          2025"},{"key":"B23","unstructured":"Press release (in Korean, 23 May 2025\n          \n          \n          \n          2025"},{"key":"B24","doi-asserted-by":"publisher","first-page":"35703","DOI":"10.1038\/s41598-025-19609-z","article-title":"Seasonal trends and molecular evolution of SARS-CoV-2 in acute respiratory illness patients during the fifth year of COVID-19, Thailand","volume":"15","author":"Puenpa","year":"2025","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7342a1","article-title":"Genomic surveillance for SARS-coV-2 variants: circulation of omicron XBB and JN.1 lineages - United States, May 2023-September 2024","volume":"73","author":"Ma","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/v16030473","article-title":"Cross-reactivity assessment of vaccine-derived SARS-coV-2 T cell responses against BA.2.86 and JN.1","volume":"16","author":"Sohail","year":"2024","journal-title":"Viruses"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ade6132","article-title":"Omicron BA.2 breakthrough infection elicits CD8(+) T cell responses recognizing the spike of later Omicron subvariants","volume":"9","author":"Kim","year":"2024","journal-title":"Sci Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e0165523","DOI":"10.1128\/spectrum.01655-23","article-title":"Longitudinal kinetics of neutralizing antibodies against circulating SARS-CoV-2 variants and estimated level of group immunity of booster-vaccinated individuals during omicron-dominated COVID-19 outbreaks in the Republic of Korea, 2022","volume":"11","author":"Lee","year":"2023","journal-title":"Microbiol Spectr"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e29329","DOI":"10.1002\/jmv.29329","article-title":"Clinical utility of quantitative immunoassays and surrogate virus neutralization tests for predicting neutralizing activity against the SARS-CoV-2 Omicron BA.1 and BA.5 variants","volume":"95","author":"Lee","year":"2023","journal-title":"J Med Virol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e70130","DOI":"10.1002\/jmv.70130","article-title":"Estimating SARS-coV-2 omicron XBB.1.5 spike-directed functional antibody levels from an anti-receptor binding domain wuhan-hu-1-based commercial immunoassay results","volume":"97","author":"S\u00e1nchez-Simarro","year":"2025","journal-title":"J Med Virol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1696676\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T06:38:34Z","timestamp":1767595114000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1696676\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":30,"alternative-id":["10.3389\/fimmu.2025.1696676"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1696676","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1696676"}}